Definition
Orphan Drug Designation
Orphan drug designation is an FDA status granted to a drug or biologic intended to treat, diagnose or prevent a rare disease or condition, generally one affecting fewer than 200,000 people in the United States, that qualifies the sponsor for development incentives.
2 min readReviewed September 14, 2026
Also known as: Orphan designation, Orphan drug status, ODD
Key facts
- Legal basis
- Orphan Drug Act of 1983 (FD&C Act Section 526)
- Regulations
- 21 CFR Part 316
- Administered by
- FDA Office of Orphan Products Development (OOPD)
- Rare disease threshold
- Fewer than 200,000 people in the U.S., or no expected cost recovery
- Main incentive
- 7 years of orphan drug exclusivity after approval for the designated use
What is orphan drug designation?
The Orphan Drug Act of 1983 set out to encourage treatments for diseases too rare to attract commercial investment. A product qualifies if it targets a disease or condition affecting fewer than 200,000 people in the United States, or more than that when there is no reasonable expectation that U.S. sales will recover development costs.
Designation is not approval. It is a decision about the disease and the scientific rationale for the product, and the sponsor must still win approval through a New Drug Application (NDA) or Biologics License Application (BLA). Designation must be requested before the marketing application for that use is submitted.
Incentives of orphan designation
A designated product can qualify for:
- 7 years of orphan drug exclusivity if it is approved for the designated use, blocking approval of the same drug for the same use unless a later product is shown to be clinically superior.
- A federal tax credit for qualified clinical testing costs, set at 25 percent since the Tax Cuts and Jobs Act of 2017.
- An exemption from the Prescription Drug User Fee Act (PDUFA) application fee when the application covers only orphan-designated uses.
- Eligibility for FDA orphan products grants that fund clinical studies.
Why orphan designation matters
Rare diseases account for a substantial share of recent novel drug approvals. Designation and approval data show which rare disease markets are filling up and which sponsors are building portfolios there.
Orphan status also affects pricing policy. The Inflation Reduction Act excludes certain orphan drugs from Medicare drug price negotiation, and a 2025 law widened that exclusion to drugs designated for more than one rare disease, provided they are approved only for those diseases. Many drugs hold orphan designations for some uses and broad non-orphan indications for others, so designation alone does not mean a drug serves a small population.